

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Guideline scope

Type 2 diabetes in adults: management (Medicines update)

This guideline will update the NICE guideline on type 2 diabetes in adults: management (NG28).

NICE is updating its diabetes guidelines. NICE will update the guideline on type 2 diabetes in adults: management (NG28) as a series of updates. This scope is about updating the section on drug treatment.

The guideline will be developed using the methods and processes outlined in [developing NICE guidelines: the manual](#).

This guideline will also be used to update the NICE [quality standard](#) for diabetes in adults.

Why the update is needed

Topic experts advised us on areas for the update. The previous update of the guideline focussed on the cardiovascular benefits of drug treatment. In this update the drug treatment section will be updated in full.

During scoping we identified another area to cover:

- Initial treatment other than metformin monotherapy for specific groups.

1 Who the guideline is for

This guideline is for:

- Healthcare professionals in the NHS
- Commissioners and providers of NHS healthcare services
- People with diagnosed type 2 diabetes, their families and carers.

1 It may also be relevant for:

- 2 • Voluntary organisations and patient support groups

3

4 NICE guidelines cover health and care in England. Decisions on how they apply in
5 other UK countries are made by ministers in the [Welsh Government](#), [Scottish](#)
6 [Government](#) and [Northern Ireland Executive](#).

7 **Equality considerations**

8 NICE has carried out an [equality impact assessment](#) during scoping. The
9 assessment:

- 10 • lists equality issues identified, and how they have been addressed
11 • explains why any groups are excluded from the scope.

12 The guideline will look at inequalities relating to age, disability and ethnicity.

13 **2 What the updated guideline will cover**

14 **2.1 Who is the focus?**

15 **Groups that will be covered**

- 16 • Adults (aged 18 years and older) with type 2 diabetes.

17

18 Specific consideration will be given to people:

- 19 • with moderate or severe frailty
20 • with early onset type 2 diabetes (age <40)
21 • with type 2 diabetes first diagnosed at age ≥80
22 • with long-term conditions for example heart failure, other cardiovascular diseases,
23 chronic kidney disease or non-alcoholic fatty liver disease
24 • at high risk of developing cardiovascular disease
25 • in specific ethnic groups
26 • with severe mental illness
27 • with cognitive impairment, for example those with dementia

- 1 • with a learning disability
- 2 • with obesity.

3 **Groups that will not be covered**

- 4 • People who are planning pregnancy or are already pregnant (this is covered by
- 5 the [NICE guideline on diabetes in pregnancy: management from preconception to](#)
- 6 [the postnatal period \(NG3\)](#)).

7 **2.2 Settings**

8 **Settings that will be covered**

- 9 • All settings where NHS-funded care is provided.

10 **2.3 Activities, services or aspects of care**

11 **Key areas that will be covered in this update**

12 Please note that NICE will be updating the guideline on type 2 diabetes in adults:
13 management (NG28) as a series of updates.

14 In this update, we will look at evidence on drug treatments for managing type 2
15 diabetes. We will consider making new recommendations or updating existing
16 recommendations in this area only.

17 Note that guideline recommendations will normally fall within licensed indications;
18 exceptionally, and only if clearly supported by evidence, use outside a licensed
19 indication may be recommended. The guideline will assume that prescribers will use
20 a medicine's summary of product characteristics to inform decisions made with
21 individual patients.

22 **Changes to the guideline**

23 For the [section on drug treatment](#), we are reviewing all recommendations apart from
24 the ones under the headings 'insulin-based treatments' and 'insulin delivery'.

1 Recommendations in areas that are being retained from the existing guideline may
2 be edited to ensure that they meet current editorial standards and reflect the current
3 policy and practice context.

4 **Related NICE guidance**

5 **Published**

- 6 • [Hypertension in adults: diagnosis and management](#) (2022) NICE guideline NG136
- 7 • [Chronic kidney disease: assessment and management \(update of CG182\)](#) (2021)
8 NICE guideline NG203
- 9 • [Multimorbidity: clinical assessment and management](#) (2016) NICE guideline NG56
- 10 • [Diabetic foot problems: prevention and management](#) (2015) NICE guideline NG19
- 11 • [Diabetes \(type 1 and type 2\) in children and young people: diagnosis and](#)
12 [management](#) (2015) NICE guideline NG18
- 13 • [Type 1 diabetes in adults: diagnosis and management](#) (2015) NICE guideline
14 NG17
- 15 • [Diabetes in pregnancy: management from preconception to the postnatal period](#)
16 (2015) NICE guideline NG3
- 17 • [Obesity: identification, assessment and management](#) (2014) NICE guideline
18 CG189
- 19 • [Cardiovascular disease: risk assessment and reduction, including lipid](#)
20 [modification](#) (2014) NICE guideline CG181. (This guideline is also being updated.
21 Publication of the [update of the NICE guideline on cardiovascular disease](#) is
22 expected in May 2023.)
- 23 • [Peripheral arterial disease: diagnosis and management](#) (2012) NICE guideline
24 CG147
- 25 • [Type 2 diabetes: prevention in people at high risk](#) (2012) NICE guideline PH38
- 26 • [Preventing type 2 diabetes: population and community-level interventions](#) (2011)
27 NICE guideline PH35
- 28 • [Obesity prevention](#) (2006) NICE guideline CG43
- 29

1 **In development**

- 2 • [Diabetic retinopathy](#) NICE guideline. Expected publication date April 2024
- 3 • [Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and](#)
- 4 [coronary artery disease](#) NICE technology appraisal guidance. Publication date to
- 5 be confirmed
- 6 • [Semaglutide for treating type 2 diabetes](#) NICE technology appraisal guidance.
- 7 Publication date to be confirmed
- 8 • [Dulaglutide for treating type 2 diabetes](#) NICE technology appraisal guidance.
- 9 Publication date to be confirmed
- 10 • [Sotagliflozin for treating type 2 diabetes \[ID1657\]](#)
- 11 • [Canagliflozin for treating chronic kidney disease in people with type 2 diabetes](#)
- 12 [\[ID1653\]](#) NICE technology appraisal guidance. Publication date to be confirmed
- 13 • [Diabetes \(type 1 and type 2\) in children and young people: diagnosis and](#)
- 14 [management - medicines for type 2 diabetes \(update\)](#) NICE guideline. Expected
- 15 publication date April 2023
- 16 • [Diabetes - buccal insulin \[ID311\]](#) NICE technology appraisal guidance. Publication
- 17 date to be confirmed.
- 18 • [Empagliflozin for reducing the risk of cardiovascular events in type](#)
- 19 [2 diabetes \[ID1037\]](#) NICE technology appraisal guidance. Publication date to be
- 20 confirmed
- 21 • [Finerenone for treating chronic kidney disease in people with type](#)
- 22 [2 diabetes \[ID3773\]](#) NICE technology appraisal guidance. Publication date to be
- 23 confirmed
- 24 • [Tirzepatide for treating type 2 diabetes \[ID3938\]](#) NICE technology appraisal
- 25 guidance. Expected publication date April 2023

26 **NICE guidance that will be integrated into this guideline**

- 27 • [Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type](#)
- 28 [2 diabetes](#) (2019) NICE technology appraisal guidance 583
- 29 • [Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes](#) (2019)
- 30 NICE technology appraisal guidance 572

- 1 • [Dapagliflozin in triple therapy for treating type 2 diabetes](#) (2016) NICE technology
2 appraisal guidance 418
- 3 • [Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2](#)
4 [diabetes](#) (2016) NICE technology appraisal guidance 390
- 5 • [Empagliflozin in combination therapy for treating type 2 diabetes](#) (2015) NICE
6 technology appraisal guidance 336
- 7 • [Canagliflozin in combination therapy for treating type 2 diabetes](#) (2014) NICE
8 technology appraisal guidance 315
- 9 • [Dapagliflozin in combination therapy for treating type 2 diabetes](#) (2013) NICE
10 technology appraisal guidance 288
- 11 • [Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus](#)
12 (2008) NICE technology appraisal guidance 151

13 **NICE guidance that will be updated by this guideline**

- 14 • [Type 2 diabetes in adults: management](#) (2022) NICE guideline NG28

15 **NICE guidance about the experience of people using NHS services**

16 NICE has produced the following guidance on the experience of people using the
17 NHS. This guideline will not include additional recommendations on these topics
18 unless there are specific issues related to type 2 diabetes in adults:

- 19 • [Shared decision making](#) (2021) NICE guideline NG197
- 20 • [Medicines optimisation](#) (2015) NICE guideline NG5
- 21 • [Patient experience in adult NHS services](#) (2012) NICE guideline CG138
- 22 • [Service user experience in adult mental health](#) (2011) NICE guideline CG136
- 23 • [Medicines adherence](#) (2009) NICE guideline CG76

24

25 **2.4 Economic aspects**

26 We will take economic aspects into account when making recommendations. We
27 will review the economic evidence and carry out economic analyses, using an NHS
28 and personal social services perspective.

1 The model used in the February 2022 version of the guideline will be updated and
2 expanded for this guideline update – see the [health economic model report](#). The
3 treatment effects in the revised model will be based upon the clinical outcomes from
4 the new update's systematic review. Results will be stratified by:

- 5 • line of treatment and
- 6 • specific risk groups (for example people with existing cardiovascular disease).

7 It is intended that this revised model will also be used or adapted for future NICE
8 guidance on medicines for Type 2 diabetes.

9 **2.5 Key issues and draft questions**

10 While writing the scope for this updated guideline, we have identified the following
11 key issue and draft questions related to it:

12 1 Drug treatment

13 1.1 For different population subgroups, which individual or combinations
14 of medicines are most clinically and cost effective as initial treatment to
15 manage type 2 diabetes? This should include but may not be limited to
16 medicines within the following classes:

- 17 – alpha-glucosidase inhibitors
- 18 – biguanides
- 19 – DPP-4 inhibitors
- 20 – GLP-1 receptor agonist
- 21 – meglitinides
- 22 – sulfonylureas
- 23 – SGLT2 inhibitors and
- 24 – thiazolidinediones.

25

26 1.2 Which medicines are most clinically and cost effective for managing
27 type 2 diabetes when current treatment has not given adequate
28 response? This should cover:

- 1 – which medicines to use, including, but not limited to, medicines within
- 2 the following classes: alpha-glucosidase inhibitors, biguanides, DPP-4
- 3 inhibitors, GLP-1 receptor agonist, meglitinides, sulfonylureas, SGLT2
- 4 inhibitors, and thiazolidinediones
- 5 – approaches to optimise treatment (including combination treatment,
- 6 switching to different therapies, de-escalation and stopping previous
- 7 therapies), and
- 8 – consideration of different population subgroups.

9
10 Current NICE technology appraisal recommendations will be integrated into the
11 guideline within the clinical context.

12 The key issues and draft questions will be used to develop more detailed review
13 questions, which will guide the systematic review of the literature.

14 **2.6 Main outcomes**

15 The main outcomes that may be considered when searching for and assessing the
16 evidence are:

- 17 • health related quality of life
- 18 • all-cause mortality
- 19 • cardiovascular mortality
- 20 • major cardiovascular events (for example nonfatal stroke, nonfatal myocardial
- 21 infarction, unstable angina, hospitalisation for heart failure)
- 22 • renal events (for example acute kidney injury, persistent signs of worsening
- 23 kidney disease, development of end stage kidney disease, death from renal
- 24 cause)
- 25 • serious adverse events (for example cardiac arrhythmia, diabetic ketoacidosis, falls
- 26 requiring hospitalisation)
- 27 • remission
- 28 • changes in HbA1c
- 29 • changes in weight or body mass index (BMI)
- 30 • frequency, timing (for example: nocturnal) and severity of hypoglycaemic episodes

1 **3 NICE quality standards**

2 **3.1 NICE quality standards**

3 **NICE quality standards that may need to be revised or updated when this** 4 **guideline is published**

- 5 • [Diabetes in adults](#) (2016) NICE quality standard 6

6

7 **Further information**

This is the draft scope for consultation with registered stakeholders. The consultation dates are 3 October 2022 to 31 October 2022.

The guideline is expected to be published in December 2024.

You can follow progress of the [guideline](#).

Our website has information about how [NICE guidelines](#) are developed.

8 © NICE [2024]. Subject to [Notice of rights](#).